VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Results of Operations and Financial Condition

VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02

Results of Operations and Financial
Condition.

On February27, 2017, ViewRay, Inc. (the Company) issued a press
release announcing certain financial results for the fourth
quarter and full year ended December31, 2016. The press release
is attached hereto as Exhibit 99.1.

The information in this Item2.02 of this Current Report on Form
8-K and the Exhibit 99.1 attached hereto shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended (the Securities Act), or
incorporated by reference in any filing of ViewRay, Inc. under
the Securities Act or the Exchange Act, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.

Item7.01 Regulation FD Disclosure.

The information set forth under Item2.02 of this Current Report
on Form 8-K is incorporated by reference into this Item7.01.

The information in this Item7.01 of this Current Report on Form
8-K and the Exhibit 99.1 attached hereto shall not be deemed
filed for purposes of Section18 of the Exchange Act, or otherwise
subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act, or incorporated by reference in
any filing of ViewRay, Inc. under the Securities Act or the
Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.

Item8.01 Other Events.

On February27, 2017, the Company announced that it received
510(k) clearance from the U.S. Food and Drug Administration to
market the MRIdian Linac system, the Companys next generation
linear accelerator-based MRI guided radiation therapy system.

Item9.01 Financial Statements and Exhibits.
(d) Exhibits.

ExhibitNumber

Description

99.1 Press Release dated February 27, 2017.


About VIEWRAY, INC. (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

VIEWRAY, INC. (NASDAQ:VRAY) Recent Trading Information

VIEWRAY, INC. (NASDAQ:VRAY) closed its last trading session up +0.95 at 5.71 with 10,170 shares trading hands.

An ad to help with our costs